Author's response to reviews

Title: Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report

Authors:

Julien Vionnet (julien.vionnet@chuv.ch)
Manuel Pascual (manuel.pascual@chuv.ch)
Haithem Chtioui (haithem.chtioui@chuv.ch)
Emiliano Giostra (emiliano.giostra@gmail.com)
Pietro E Majno (pietro.majno@hcuge.ch)
Laurent A Decosterd (laurentarthur.decosterd@chuv.ch)
Darius Moradpour (darius.moradpour@chuv.ch)

Version: 2
Date: 11 December 2014

Author's response to reviews: see over
Division of Gastroenterology and Hepatology

Darius Moradpour, M.D.
Professor and Chief
Phone +41 21 314 47 23 (direct line)
Phone +41 21 314 47 14 (secretariat)
Fax +41 21 314 47 18
Darius.Moradpour@chuv.ch
www.gastro-hepato.ch

Lausanne, December 7th, 2014

Dear Editor,

Uploaded to the BMC Gastroenterology online submission site, please find the manuscript entitled "Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report" that we would like to submit for consideration of publication as a Case Report.

Liver re-transplantation for graft failure due to recurrent hepatitis C is controversial, and some centers have abandoned the procedure because of poor outcomes. Here, we report a patient with terminal liver graft failure due to recurrent hepatitis C in a first allograft, in whom treatment with sofosbuvir and ribavirin allowed to perform re-transplantation. A similar situation has, to the best of our knowledge, not been reported to date. Besides addressing the setting of liver re-transplantation, this Case Report includes additional novel and important aspects, including the use of sofosbuvir and ribavirin in a patient with advanced liver failure and moderate renal dysfunction as well as close therapeutic drug monitoring of sofosbuvir, ribavirin and cyclosporine.

This work is not under consideration for publication elsewhere. All authors have approved the final version of the manuscript and have no conflict of interest to declare.

Thank you for your consideration and interest in this matter.

Sincerely,

[Signature]
Julien Vionnet, M.D.

[Signature]
Darius Moradpour, M.D.